Vectura announces VR876 regulatory approval

Vectura Group has announced that Bayer AG – the group’s partner on VR876 – has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery (method of administration) for its currently marketed product Ventavis (iloprost) using Vectura’s handheld smart nebuliser FOX device which Bayer has branded Breelib.

At 4:27pm: (LON:VEC) Vectura Group PLC share price was +1p at 135p

Story provided by